Thursday 20 December 2012
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Director Shareholding
The Company was informed on 20 December 2012 that Ed Torr, a director of the Company, exercised SAYE options over 1,785 ordinary shares of 1p each ("Ordinary Shares") at an exercise price of £3.0492 per share.
Following this transaction, Ed Torr's beneficial interest stands at 474,552 Ordinary Shares, which represents approximately 0.545 per cent. of the Company's issued ordinary share capital.
Further enquiries:
Zoe Goulding, Company Secretary
01782 771100
About Dechra
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.